<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00228124</url>
  </required_header>
  <id_info>
    <org_study_id>02-OCT-0203</org_study_id>
    <secondary_id>02-OCT-0203</secondary_id>
    <nct_id>NCT00228124</nct_id>
  </id_info>
  <brief_title>PR.7 Companion Trial: Effect of Intermittent Versus Continuous Androgen Suppression on Bone Loss and Body Composition</brief_title>
  <official_title>Effect of Intermittent Versus Continuous Androgen Suppression on Bone Loss and Body Composition in a Phase III Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ontario Cancer Research Network</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine, in patients entered on the National Cancer&#xD;
      Institute of Canada (NCIC)-PR.7 trial of intermittent versus continuous androgen ablation,&#xD;
      whether the rates of osteoporosis, fractures, and alteration in body composition are reduced&#xD;
      by intermittent androgen ablation.&#xD;
&#xD;
      There will be two groups of patients:&#xD;
&#xD;
        1. A cross-sectional group of 150 patients registered in PR.7 prior to January 1, 2002,&#xD;
           randomized between intermittent androgen suppression (IAS) and continuous androgen&#xD;
           suppression (CAS) (75 from each group). Patients who have definite bone metastases are&#xD;
           excluded from this study. Biochemical failure does not exclude the patient.&#xD;
&#xD;
        2. A longitudinal study of 150 newly accrued patients randomized between IAS and CAS (75&#xD;
           from each group). These patients will have baseline evaluation of bone loss and body&#xD;
           composition, longitudinal monitoring and follow-up on an annual basis for patients on&#xD;
           CAS and at the end of each &quot;off cycle&quot; of IAS. Patients taking bisphosphonates are&#xD;
           excluded from this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        1. To compare CAS and IAS with respect to bone mineral density (BMD): We will determine&#xD;
           whether the bone loss associated with long term CAS can be reduced by IAS by evaluation&#xD;
           of:&#xD;
&#xD;
             1. BMD,&#xD;
&#xD;
             2. biochemical markers of bone formation/resorption,&#xD;
&#xD;
             3. skeletal relevant events (SRE) (defined as pathological fracture, symptomatic&#xD;
                hypercalcemia or hypocalcemia, spinal cord compression, or need of spinal orthosis&#xD;
                for vertebral deformity or collapse).&#xD;
&#xD;
        2. To compare CAS and IAS with respect to body composition: We will determine whether the&#xD;
           reduction in muscle mass and increased fat accumulation associated with long term CAS&#xD;
           can be reduced by IAS. We will evaluate:&#xD;
&#xD;
             1. percentage fat body mass,&#xD;
&#xD;
             2. percentage lean body mass and&#xD;
&#xD;
             3. body mass index.&#xD;
&#xD;
        3. To evaluate the predictive value of germline polymorphisms in the Vitamin D receptor&#xD;
           (VDR) gene for bone loss&#xD;
&#xD;
      Eligible Patients for PR.7:&#xD;
&#xD;
        1. Histologically confirmed prostate cancer (PCa)&#xD;
&#xD;
        2. Completed radiotherapy to the prostatic area more than 12 months prior to randomization&#xD;
&#xD;
        3. Rising prostate specific antigen (PSA) level (serum PSA &gt; 3 ng/ml (3 μg/L)) and higher&#xD;
           than the lowest level recorded previously since the end of radiotherapy (i.e. higher&#xD;
           than the post-radiotherapy nadir)&#xD;
&#xD;
        4. No definite evidence of distant metastasis (radiological changes compatible with&#xD;
           non-malignant diseases are acceptable)&#xD;
&#xD;
        5. No prior hormonal therapy with the exception of neo-adjuvant cytoreduction prior to&#xD;
           radical radiotherapy or prostatectomy for a maximum duration of 12 months and completed&#xD;
           at least 12 months prior to randomization&#xD;
&#xD;
      Evaluation during protocol treatment will take place to assess differences in BMD, body&#xD;
      composition, biochemical and genetic markers of bone disease in the two groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2004</start_date>
  <completion_date>April 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <enrollment>300</enrollment>
  <condition>Prostate Cancer</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed PCa&#xD;
&#xD;
          -  Completed radiotherapy to the prostatic area more than 12 months prior to&#xD;
             randomization&#xD;
&#xD;
          -  Rising PSA level (serum PSA &gt; 3 ng/ml (3 μg/L)) and higher than the lowest level&#xD;
             recorded previously since the end of radiotherapy (i.e. higher than the&#xD;
             post-radiotherapy nadir)&#xD;
&#xD;
          -  No definite evidence of distant metastasis (radiological changes compatible with&#xD;
             non-malignant diseases are acceptable)&#xD;
&#xD;
          -  No prior hormonal therapy with the exception of neo-adjuvant cytoreduction prior to&#xD;
             radical radiotherapy or prostatectomy for a maximum duration of 12 months and&#xD;
             completed at least 12 months prior to randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe osteoporosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Klotz, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurence Klotz, MD, FRCSC</last_name>
    <phone>416-480-4673</phone>
    <email>laurence.klotz@sw.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunnybrook and Women's College Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlene Kebabdjian, CRA</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>2890</phone_ext>
      <email>marlene.kebabdjian@sw.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 27, 2005</study_first_submitted>
  <study_first_submitted_qc>September 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <last_update_submitted>January 25, 2006</last_update_submitted>
  <last_update_submitted_qc>January 25, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2006</last_update_posted>
  <keyword>Prostate cancer</keyword>
  <keyword>Continuous androgen suppression</keyword>
  <keyword>Intermittent androgen suppression</keyword>
  <keyword>Bone loss</keyword>
  <keyword>Osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

